Entities / Company
Stereotaxis.
American medical robotics company
- Reports this week
- 1
- Active events
- 1
- Connections
- 26
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Gone quiet
No new reports in 90+ days-
Citigroup provided analyst ratings on Stereotaxis on July 17, 2026.Some support1 report
-
Citigroup restated a market outperform rating for Stereotaxis, while MarketBeat provided average rating and target price.Some support1 report
-
Stereotaxis announced that David Fischel was appointed Chairman and CEO, and the company filed an offering pursuant to an SEC registration statement.Some support1 report1 development inside
-
Stereotaxis, led by CEO David Fischel, participated in the MAGiC catheter study at Vilnius University Hospital on July 1, 2025.Speculative1 report
-
Stereotaxis technology has been successfully used to treat patients across the United States, Europe, and Asia.Some support1 report
-
Stereotaxis received FDA clearance for commercial launch and submitted applications regarding its procedures in the U.S. market.Some support2 reports2 developments inside
-
Stereotaxis received FDA clearance for a diagnostic catheter and utilizes Genesis robotic navigation systems.Some support2 reports
-
Stereotaxis shares underperformed the market on August 8, 2025.Some support1 report
-
David Fischel was appointed Chairman and CEO of Stereotaxis on August 8, 2025.Some support1 report
-
Stereotaxis CEO David Fischel and other experts are involved in a conference in Atlanta focused on ablation techniques, pioneered by the Heart Rhythm Society.Some support2 reports
-
Stereotaxis CEO David Fischel is scheduled to present at conferences in New York City.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Stereotaxis this week
News at the entities that move Stereotaxis most-
FDA StructuralPolitical rhetoric is challenging the market approval process for vaccines by the FDA.Moves Stereotaxis
-
MarketBeat Mentioned togetherMarketBeat provided average ratings and target prices, while Jefferies Financial Group began coverage with a buy rating for Crane NXT.Moves Stereotaxis
-
Europe Shared contextMilei pitches Argentina as a regulation-free AI haven, contrasting its hands-off approach with European regulations.Moves Stereotaxis
-
Citigroup Mentioned togetherCitigroup increased its price target on GE Healthcare stock.Moves Stereotaxis
-
St. Louis Shared contextSt. Louis' economy suffered due to the absence of a river bridge connecting it to Indiana.Moves Stereotaxis
-
company Mentioned togetherRichard McGuire purchased company shares on November 2, 2026.Moves Stereotaxis
Connections
The 8 strongest of 26, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
David Fischel Structural
David Fischel holds the executive roles of Chairman and CEO at Stereotaxis.
-
FDA Structural
FDA formally regulates Stereotaxis' medical devices, granting clearance necessary for market entry and commercial launch.
-
Heart Rhythm Society Operational
Stereotaxis showcases its technology and participates in initiatives organized by the Heart Rhythm Society.
-
Europe Shared context
Stereotaxis operates and commercializes its technology within the European market.
-
MarketBeat Mentioned together
MarketBeat provides average rating and target price coverage for Stereotaxis.
-
Citigroup Mentioned together
Citigroup provided analyst ratings on Stereotaxis.
-
company Mentioned together
Stereotaxis is mentioned in the context of the general concept of a company.
-
St. Louis Shared context
Stereotaxis is located and operates within the geographical context of St. Louis, Missouri.
History
Events by the month they beganOctober 2026
1 eventJuly 2026
2 eventsJune 2026
9 events- Stereotaxis announced that David Fischel was appointed Chairman and CEO, and the company filed an offering pursuant to an SEC registration statement.
- Stereotaxis, led by CEO David Fischel, participated in the MAGiC catheter study at Vilnius University Hospital on July 1, 2025.
- Stereotaxis technology has been successfully used to treat patients across the United States, Europe, and Asia.
- Stereotaxis received FDA clearance for commercial launch and submitted applications regarding its procedures in the U.S. market.
- Stereotaxis received FDA clearance for a diagnostic catheter and utilizes Genesis robotic navigation systems.
- Stereotaxis shares underperformed the market on August 8, 2025.
- David Fischel was appointed Chairman and CEO of Stereotaxis on August 8, 2025.
- Stereotaxis CEO David Fischel and other experts are involved in a conference in Atlanta focused on ablation techniques, pioneered by the Heart Rhythm Society.
- Stereotaxis CEO David Fischel is scheduled to present at conferences in New York City.